CoreAge Rx vs MYRNK
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and MYRNK head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 69 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make MYRNK a bad call — it's best for a reader who wants glp-1 care and peptide or hormone lines from one account, and who will get a firm figure before starting. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | MYRNK | |
|---|---|---|
| Brief Score | 94/100 (A) | 69/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | From $197/mo (compounded) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | From $297/mo (compounded) |
| Coverage | US only; restrictions by state, confirmed at intake | Not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
MYRNK: New to the tracker on 13 September 2026, read live off the provider's own pages that day rather than taken on trust. There is no earlier reading here to compare against, so the direction is "new" rather than stable — a first observation is not a trend. Every line on this storefront is a "From" price, so there is no ceiling to track a movement against yet; the next reading will have to establish whether the floor is also the rate.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.